

Therapeutic Innovation Symposium

December, 18th-19th, 2014

Amphithéâtre Buffon
Université Paris Diderot

15 rue Hélène Buffon - Paris 13^e

Thursday, December 18th

- 8:45-9:00 **Introduction** - Christian Boitard (Paris)
- 9:00-9:45 **Keynote lecture: Therapeutic antibodies to harness tolerance mechanisms of the Immune System** – Herman Waldmann (Oxford)
- 9:45-10:05 **From the lab to the market: actors, trends, stakeholders and the role of Aviesan** – Marco Fiorini (Paris)
- Session 1 – Tools, innovative technologies**
Chair: Jean-Marc Grognet (Saclay)
- Biological aspects**
- 10:05-10:25 **Anti-PCSK9 therapeutic antibodies** – Catherine Boileau (Paris)
- 10:25-10:45 **Adipose derived stromal cells for osteoarthritis** - Christian Jorgensen (Montpellier)
- 10:45-11:15 *Coffee break*
- 11:15-11:35 **Embryonic stem cells and cardiac regeneration** – Philippe Menasché (Paris)
- 11:35-11:55 **Fueling hematopoietic stem cell differentiation** - Naomi Taylor (Montpellier)
- Medical devices**
- 11:55-12:15 **Insulin pump becomes artificial pancreas** – Eric Renard (Montpellier)
- 12:15-12:35 **Cartilage repair: current concepts** – Didier Mainard (Nancy)
- 12:35-12:55 **Carmat total artificial heart** - Christian Latrémouille (Paris)
- 12:55-14:05 *Lunch buffet*
- Session 2 : New preclinical models, animal model vs clinical trials**
Chair: Richard Moreau (Paris)
- 14:05-14:25 **Genome editing with TALE and CRISPR/Cas9 nucleases** – Carine Giovannangeli (Paris)
- 14:25-14:45 **Vagal stimulation for weight control** – Charles-Henri Malbert (Rennes)
- 14:45-15:05 **Clinical trial methodology in chronic diseases: Reducing waste of research** – Philippe Ravaud (Paris)
- 15:05-15:25 **Clinical trial in chronic hepatitis C** - Patrick Marcellin (Paris)
- 15:25-15:55 *Coffee break*
- 15:55-16:35 **Open innovation: the new model of Public Private Partnership / Sanofi** – Isabelle Thizon De Gaulle (Paris)

16:35-17:30 **Round table - Therapeutic innovation**

Introduction - Renato Monteiro (Paris)

Drugs and Diagnostics based on the Gut Microbiome / ENTEROME (PME) - Pierre Belichard (Paris)

From basic research to industrial development : genesis of the biotech company HEMARINA - Franck Zal (Morlaix)

Inserm Transfert - Pascale Augé (Paris)

CEA Investissement - Célia Hart (Paris)

Friday, December 19th

Session 3 : Biomarkers

Chair: Francis Berenbaum (Paris)

9:00-9:20 **Omics-based efficacy follow-up** – Christophe Junot (Paris)

9:20-9:40 **Combination of genetic screening with platelet function testing for a personalized antiplatelet therapy** – Jean-Sébastien Hulot (Paris)

9:40-10:00 **Genomics for adrenal tumors molecular markers development** – Jérôme Bertherat (Paris)

10:00-10:20 **Pharmacokinetic-pharmacodynamic relationship (PK-PD) of therapeutic antibodies** – Gilles Paintaud (Tours)

10:20-10:40 **Imaging biomarkers for the diagnosis of vulnerable atherosclerotic plaques** – Alexis Broisat (Grenoble)

10:40-11:10 *Coffee break*

Session 4 : Local delivery

Chair: Florence Noble (Paris)

11:10-11:30 **Cardiovascular biomaterials for controlled release** – Didier Letourneur (Paris)

11:30-11:50 **Microparticles for controlled local drug delivery** – Juergen Siepmann (Lille)

11:50-12:10 **Composite droplets: Delivering and creating drugs in-situ with an ultrasound scanner** – Olivier Couture (Paris)

12:10-13:20 *Lunch buffet*

Session 5 : *in silico* investigation, bioinformatics, biostatistics, big data

Chair: François Hirsch (Paris)

13:20-13:40 ***in silico* approaches to assist drug discovery** – Bruno Villoutreix (Paris)

13:40-14:00 **Healthcare Information Systems: the challenges of semantic interoperability** – Marie-Christine Jaulent (Paris)

14:00-14:20 **Big data & healthcare, new technologies can open the way to innovation / Orange Healthcare** - Isabelle Hilali (Paris)

14:20-14:40 **Neuroimaging techniques for early diagnosis and prognosis : application to psychiatry** - Fouad Hadj Selem (Saclay)

14:40-15:00 **Conclusion** - Christian Boitard, Franck Lethimonnier (Paris)